Privi Speciality Chemicals Limited announces an acquisition

Share exchange ratio: The independent valuer, RBSA Valuation Advisors LLP, recommended 1 fully paid-up equity share of Privi Speciality Chemicals Limited (PSCL) for every 135 fully paid-up equity shares of Privi Fine Sciences Private Limited (PFSPL). The shares were valued at Rs 10 face value each. No shares are to be issued for Privi Biotechnologies Private Limited because it is PSCL’s wholly owned subsidiary. ^[1]

The ratio follows directly from the concluded per-share values in the Valuation Report:

^[2]

How it aligns with P/E or EV/EBITDA: The 135:1 ratio is therefore an equity-value-per-share ratio, not a directly disclosed P/E or EV/EBITDA exchange multiple. The report does not present a standalone P/E-based ratio. Although it used the comparable companies multiple method for 50% of PSCL’s valuation, the disclosed summary does not provide the underlying P/E multiple or its numerical contribution.

More importantly, RBSA explicitly did not rely on EV/EBITDA. It concluded that available forward EBITDA estimates and comparable-company trading multiples would not provide a meaningful valuation basis at that stage; for PFSPL, it instead used management projections and a DCF valuation. ^[2]

Thus, the ratio is internally consistent with the report’s concluded values—PSCL was valued at approximately 135 times PFSPL’s value per share—but it should not be interpreted as evidence that PSCL traded at, or was exchanged at, a 135x P/E or EV/EBITDA multiple.

The merger would not automatically worsen either ratio merely because all liabilities transfer. The effect depends on the composition of those liabilities and the pro-forma equity and earnings base.

• Debt-to-equity: The Scheme provides for all assets, liabilities, duties and obligations of both transferor companies to vest in Privi Speciality Chemicals, while inter-company balances, loans and advances are cancelled. ^[3] Accordingly, only external interest-bearing borrowings should be added to consolidated debt; trade payables and other operating liabilities should not be treated as debt. The ratio would rise if the transferors’ external borrowings exceed the incremental equity recognised in the merger, but could remain broadly unchanged or improve if the transferred liabilities are largely operating liabilities or are offset by transferred assets and reserves.
• Interest coverage: The ratio would weaken only to the extent that transferred interest-bearing debt creates additional finance costs without a proportionate increase in operating profit or EBITDA. If the transferred liabilities are predominantly non-interest-bearing, the liability transfer would have little direct effect on interest coverage. PBPL’s FY26 financial results, for example, reported no finance cost but a loss before tax of Rs 484.42 Lakhs, which would not provide incremental earnings cover on a standalone basis. ^[4]
• Reference point: The existing consolidated group’s FY26 debt-equity calculation reported net liabilities of Rs 93,876.35 Lakhs, equity of Rs 144,060.91 Lakhs and a ratio of 0.65 times. ^[5] This is not the post-merger pro-forma ratio.

Conclusion: The anticipated direction is potentially higher leverage and weaker interest coverage if the transferors bring in external interest-bearing liabilities. However, the exact post-merger ratios cannot be quantified from the cited pro-forma extracts because the transferors’ debt, finance cost, equity adjustments and consolidated operating profit are not stated. The Scheme’s stated benefits of improved cash and debt management could support the ratios after integration, but that is a management rationale rather than a pro-forma calculation. ^[6]

The remaining gating items are NCLT sanction, any approvals or consents required from competent authorities, applicable creditor approvals, and filing the certified NCLT order with the ROC. The stock-exchange clearance is substantially complete, so it is not the main outstanding condition.

Remaining conditions precedent

• NCLT sanction: The scheme must receive the final sanction of the Mumbai Bench of the NCLT under Sections 230–232 of the Companies Act. The September 7, 2026 NCLT order only directed the equity-shareholder meeting; it did not constitute final sanction of the Scheme. ^[7]
• Requisite shareholder and creditor majorities: The Scheme requires approval by the requisite majorities of shareholders and creditors of the parties, to the extent required by applicable law or directed by the Tribunal or another authority. ^[8] The notice does not identify a separately named creditor consent or a specific creditor class threshold beyond this conditional requirement.
• SEBI public-shareholder voting condition: For the listed transferee, the Scheme can proceed only if votes cast by public shareholders in favour exceed votes cast against, as required under the applicable SEBI scheme circular. ^[9]
• Other statutory or regulatory consents: Any permissions required from an “Appropriate Authority” for implementing the Scheme must be obtained. The notice does not name an additional specific regulator or consent beyond this broad statutory catch-all. ^[9]
• ROC filing: Certified copies of the NCLT order must be filed by the parties with the Registrar of Companies. This filing is expressly included as a condition precedent; the Scheme becomes effective only after the last of the specified conditions is satisfied. ^{[10] [11]}

Already completed or substantially addressed

The Scheme required no-objection letters from NSE and BSE under Regulation 37 of the SEBI Listing Regulations. The company reported receiving the NSE observation letter on May 5, 2026 and the BSE observation letter on May 6, 2026. ^[12] These should therefore be treated as completed pre-conditions, subject to any residual compliance or conditions attached to those letters.

Timeline

Management’s reported expectation was that the amalgamation would be completed within FY27, i.e., by March 31, 2027. ^[13] No more granular management timetable was reported for the NCLT hearing, sanction order, or subsequent ROC filing. Accordingly, the practical completion window is after the October 27, 2026 shareholder meeting and before the end of FY27, but the exact effective date remains dependent on NCLT scheduling, any creditor or authority requirements, and the timing of ROC filing. ^{[14] [7]}